[Glucose intolerance in chronic renal failure]. 1996

Y Matsushita, and S Hara
Toranomon Hospital Kidney Center.

It has been recognized that glucose intolerance is a common finding in patients with chronic renal failure (CRF). Insulin resistance and impaired insulin secretion contribute to the pathogenesis of glucose intolerance. The resistance to insulin action is commonly observed in chronic renal failure and mainly due to impaired glucose uptake by muscle. In contrast, insulin secretion in response to hyperglycemia is variable: increased, decreased and normal. Recent studies reported that high PTH levels impaired insulin secretion from pancreatic islets. In this review, we mention the mechanism of glucose intolerance in chronic renal failure.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007333 Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS. Insulin Sensitivity,Resistance, Insulin,Sensitivity, Insulin
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D010281 Parathyroid Hormone A polypeptide hormone (84 amino acid residues) secreted by the PARATHYROID GLANDS which performs the essential role of maintaining intracellular CALCIUM levels in the body. Parathyroid hormone increases intracellular calcium by promoting the release of CALCIUM from BONE, increases the intestinal absorption of calcium, increases the renal tubular reabsorption of calcium, and increases the renal excretion of phosphates. Natpara,PTH (1-84),PTH(1-34),Parathormone,Parathyrin,Parathyroid Hormone (1-34),Parathyroid Hormone (1-84),Parathyroid Hormone Peptide (1-34),Hormone, Parathyroid
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000078790 Insulin Secretion Production and release of insulin from PANCREATIC BETA CELLS that primarily occurs in response to elevated BLOOD GLUCOSE levels. Secretion, Insulin
D018149 Glucose Intolerance A pathological state in which BLOOD GLUCOSE level is less than approximately 140 mg/100 ml of PLASMA at fasting, and above approximately 200 mg/100 ml plasma at 30-, 60-, or 90-minute during a GLUCOSE TOLERANCE TEST. This condition is seen frequently in DIABETES MELLITUS, but also occurs with other diseases and MALNUTRITION. Impaired Glucose Tolerance,Glucose Intolerances,Glucose Tolerance, Impaired,Glucose Tolerances, Impaired,Impaired Glucose Tolerances,Intolerance, Glucose,Intolerances, Glucose,Tolerance, Impaired Glucose,Tolerances, Impaired Glucose

Related Publications

Y Matsushita, and S Hara
November 1983, Kidney international. Supplement,
Y Matsushita, and S Hara
November 1994, Angiology,
Y Matsushita, and S Hara
March 1985, The Journal of clinical investigation,
Y Matsushita, and S Hara
January 1992, American journal of nephrology,
Y Matsushita, and S Hara
October 1968, Lancet (London, England),
Y Matsushita, and S Hara
August 1990, The Journal of laboratory and clinical medicine,
Y Matsushita, and S Hara
December 1983, Kidney international. Supplement,
Y Matsushita, and S Hara
February 2005, Nihon rinsho. Japanese journal of clinical medicine,
Copied contents to your clipboard!